Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 11, 2017updated 07 Dec 2021 4:39am

M&As this week: Autobio Diagnostics, MedicaMetrix, Sygnis AG

Diagnostics products developer Autobio Diagnostics plans to invest $29.33m in purchasing 75% stake in Beijing Bio-Top, an in-vitro diagnostics company based in Beijing, China.

Diagnostics products developer Autobio Diagnostics plans to invest $29.33m in purchasing 75% stake in Beijing Bio-Top, an in-vitro diagnostics company based in Beijing, China.

Urological medical devices developer MedicaMetrix will be acquired by Cardiff International in a $6m all-stock transaction.

The target company will merge into Cardiff and will operate as its subsidiary.

The acquisition enables Cardiff, a software systems developer, to enter the medical device field.

Sygnis AG intends to acquire Innova Biosciences for a purchase consideration of approximately $10m, which will be paid through $8.79m in cash and will issue up to 3.5 million shares.

The acquirer company expects the acquisition to strengthen its portfolio with a labelling technology lightning link.

Content from our partners
“Everything is custom”: Behind the scenes of medical wire solutions
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
“Sygnis AG expects the acquisition to strengthen its portfolio with a labelling technology lightning link. “

Sygnis is a molecular biology company involved in the development of novel products, while Innova Biosciences offers bioconjugation technologies and services.

Luxendo GmbH has been acquired by Bruker Corporation in a move to expand its fluorescence microscopy portfolio.

Luxendo is engaged in developing advanced single plane illumination microscopes (SPIM), while Bruker is a provider of scientific instruments and diagnostic solutions.

In a $2.99m deal, MG Med intends to acquire 17.1% stake in Oxford Cancer Biomarkers.

MG Med is engaged in molecular diagnostics, while Oxford Cancer Biomarkers is a developer of biomarker diagnostic products.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU